Charles River Laboratories Intl. Inc  

(Public, NYSE:CRL)   Watch this stock  
Find more results for CRL
75.95
0.00 (0.00%)
Jun 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 59.99 - 87.95
Open     -
Vol / Avg. 0.00/357,436.00
Mkt cap 3.39B
P/E 23.16
Div/yield     -
EPS 3.28
Shares 47.18M
Beta 1.26
Inst. own 101%
Jul 28, 2016
Q2 2016 Charles River Laboratories International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 14, 2016
Charles River Laboratories International Inc at William Blair Growth Stock Conference
Jun 8, 2016
Charles River Laboratories International Inc at Jefferies Healthcare Conference
May 11, 2016
Charles River Laboratories International Inc Annual Shareholders Meeting
May 5, 2016
Charles River Laboratories International Inc at Deutsche Bank Health Care Conference - Webcast
May 4, 2016
Q1 2016 Charles River Laboratories International Inc Earnings Release
May 4, 2016
Q1 2016 Charles River Laboratories International Inc Earnings Call - Webcast
May 4, 2016
Charles River Laboratories International Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 10.59% 11.15%
Operating margin 14.50% 15.14%
EBITD margin - 22.11%
Return on average assets 7.22% 7.72%
Return on average equity 19.71% 21.39%
Employees 8,600 -
CDP Score - -

Address

251 Ballardvale St
WILMINGTON, MA 01887-1096
United States - Map
+1-781-2226000 (Phone)
+1-978-9885665 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.

Officers and directors

James C. Foster Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
David R. Smith Executive Vice President and Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
David P. Johst Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Davide A. Molho Corporate Executive Vice President, President - Global Research Models & Services and Preclinical Services Operations
Age: 46
Bio & Compensation  - Reuters
George M. Milne Jr., Ph.D. Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert J. Bertolini CPA Independent Director
Age: 54
Bio & Compensation  - Reuters
Stephen D. Chubb Independent Director
Age: 72
Bio & Compensation  - Reuters
Deborah Turner Kochevar Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
George E. Massaro Independent Director
Age: 68
Bio & Compensation  - Reuters